Prelude Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Prelude Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,140	Closed	-$708K	–	1508
2026 Q1	$708K	Buy	21,140 +15,762	+293%	+$618K	0.05%	395
2025 Q4	$249K	Sell	5,378 -11,015	-67%	-$604K	0.02%	895
2025 Q3	$1.11M	Buy	16,393 +2,484	+18%	+$184K	0.09%	291
2025 Q2	$1.17M	Buy	13,909 +486	+4%	+$36.4K	0.11%	227
2025 Q1	$959K	Sell	13,423 -6,893	-34%	-$336K	0.07%	316
2024 Q4	$913K	Buy	+20,316	New	+$1.05M	0.06%	411

Prelude Capital Management's SLNO Position: Q2 2026 in Review

Prelude Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 21,140 shares — an estimated $708K sold.

Prelude Capital Management first reported a position in SLNO in Q4 2024 and held it in 6 quarters. The position peaked at $1.17M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Prelude Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Prelude Capital Management sold 21,140 Soleno Therapeutics shares in Q2 2026, an estimated $708K.
Prelude Capital Management first reported a position in Soleno Therapeutics in Q4 2024 and held it in 6 quarters.
Prelude Capital Management's Soleno Therapeutics position peaked at $1.17M in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.